INOGRAFT BIOTHERAPEUTICS

Stem cells for research purposes; biochemicals, namely, monoclonal antibodies for in vitro scientific or research use; decoy receptors being biochemicals for in vitro scientific or research use

Stem cell-derived drug therapies being biological preparations for the treatment of monogenetic diseases, autoimmune diseases, cancer, and aging-related diseases; stem cell-derived therapeutic pharmaceutical preparations for the treatment of monogenetic diseases, autoimmune diseases, cancer, and aging-related diseases; stem cells for therapeutic treatment of monogenetic diseases, autoimmune diseases, cancer, and aging-related diseases for medical purposes; pharmaceutical preparations as CD47 antagonists, integrin-associated proteins (IAP), and CD47 glycoproteins for the treatment of monogenetic diseases, autoimmune diseases, cancer, and aging-related diseases; monoclonal antibodies for medical purposes; monoclonal antibodies to suppress immune responses that lead to rejection of stem cell and organ transplants for medical purposes

Research and development services relating to bone marrow, stem cell, and organ transplantation; research and development in the field of stem cell therapies; research and development relating to bone marrow, stem-cell, and organ transplantation; research and development relating to pharmaceutical preparations as CD47 antagonists, integrin-associated proteins, and CD47 glycoproteins; research and development services in the field of antibodies; research and development relating to using monoclonal antibodies to suppress immune responses that lead to rejection of stem cell and organ transplants